High-Dose Folinic Acid and Fluorouracil with or Without Ifosfamide Is an Inactive Combination in Advanced Pancreatic Cancer: A Randomized Phase II Study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 3, 1996, Pages 307-310

  Di Costanzo, F ^a,i   Tagliaventi, M ^a   Carlini, P ^b   Zironi, S ^c   Mazzocchi, B ^d   Bella, M ^e   Donati, D ^f   Acito, L ^g   Maggian, P ^h   Angiona, S ^a  

^a Medical Oncology Institution of Terni   (Italy)

^b Med Oncology Institution of Roma   (Italy)

^c Medical School of Modena   (Italy)

^d Med Oncol Institution of Grosseto   (Italy)

^e Medical Oncology Institution of Parma   (Italy)

^f Med Oncology Institution of Ferrara   (Italy)

^g Med Oncology Institution of Fermo   (Italy)

^h Med Oncology Institution of Vicenza   (Italy)

ⁱ S MARIA HOSPITAL   (Italy)

Author keywords

5FU; Chemotherapy; Folinic acid; Ifosfamide; Pancreatic carcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MESNA; METOCLOPRAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; IFOSFAMIDE; LEUCOVORIN; MALE; MESNA; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 0029975668     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199606000-00021     Document Type: Article

References (19)

1. O'Connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985;3:1032-9.
2. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FMS). Cancer 1986;57:29-33.
3. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7.
4. Cullinan SA, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallison regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990;65:2207-12.
5. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol 1986;5:685-96.
6. Arbuck SG, Douglass HO, Trave F, et al. A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 1987;5:1150-6.
7. Di Costanzo F, Bartolucci R, Padalino D, et al. Phase II study with high dose folinic acid and 5-fluorouracil in advanced colorectal cancer. Cancer Invest 1988;6:133-8.
8. Piedbois P, Buyse M, Rustum Y, et al. Advanced colorectal cancer metaanalysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
9. Loehrer PJ, Williams SD, Einhorn LH, et al. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985;3:367-72.
10. Gad-El-Mawla N. Ifosfamide in advanced pancreatic cancer. A 5-year experience. Cancer Chem Pharmacol 1986;18:55-6.
11. Gad-El-Mawla N, Ziegler JL. Ifosfamide treatment of pancreatic cancer. Cancer Treat Rep 1981;65:357-8.
12. Cerny T, Martinelli G, Goldhirsch A, et al. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 1991;117: 135-8.
13. Brühl P, Günther V, Hoefer-Janker H, et al. Results obtained with fractionated ifosfamide massive dose treatment in generalized malignant tumors. Int J Clin Pharmacol 1976;14:29-39.
14. Gastrointestinal Tumor Study Group (GITSG). Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 1989;64:2010-13.
15. Ajani JA, Abbruzzese JL, Goudeau P, et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988;6:1703-7.
16. Bruckner HW, Crown JP, McKenna A, et al. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 1988;48:5570-2.
17. DeCaprio JA, Mayer RJ, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-33.
18. Loehrer PJ, Williams SD, Nichols CR. Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas. Cancer Treat Rep 1987;71:1115-6.
19. Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.